MolMed S.p.A., a biotechnology company focused on research, development, production and clinical validation of gene and cell therapies for the treatment of cancer and rare diseases, announces that with a communication pursuant to Art. 102 of Decree n. 58/1998 (Consolidated Financial Act, “TUF”), AGC Inc. (the “Offeror”) declared its intention to launch - directly or through a company of the same Offeror Group or through a newly fully owned incorporated company - a voluntary tender offer over 100% of the Company's ordinary shares against a consideration equal to Euro 0.518 per ordinary share (the "Offer").
In light of the above, the Company also announces that its Board of Directors met on March 16th, 2020 following the receipt of a communication from AGC Inc. of its intention to launch the Offer, subject, inter alia, to the subscription by the Company of an agreement with the Offeror providing a standard set of representations and warranties to be given by the Company and concerning the business of the latter (the "R&Ws"), for the sole purpose of allowing the Offeror to enter into a W&I policy with an insurance company concerning the indemnification obligations for the breach of such R&Ws (the "Agreement").
For more info:
https://www.molmed.com/sites/default/files/2020-03/PR_Announcement%20PTO_FINAL_170320_0_0.pdf